CapsoVision, Inc
No enriched coverage for $CV in the last 7 days.
No SEC Form 4 filings for $CV in the last 30 days.
See all $CV insider activity →CapsoVision, Inc (CV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CapsoVision Reports Second Quarter 2026 Financial Results SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financia
CapsoVision (NASDAQ: CV) said it launched its AI Highlights feature for the CapsoCam Plus capsule endoscopy system in international markets, including the EU. The AI flags suspected clinically relevant frames during standard processing and integrates with CapsoView and CapsoCloud workflows. The update is offered where authorized; it is not cleared by the FDA for US sale.
HARARI ELIYAHOU ET AL purchased 61,068 indirectly-held shares of CapsoVision, Inc (CV) at $6.73 ($0.41M total) on 2026-07-17.
Recent CV coverage spans insider activity, financial news and corporate actions.
The filing signals potential near-term dilution risk and incremental funding capacity via an at-the-market equity program.
The EU rollout of an AI-assisted review feature is a commercial expansion catalyst, but the release provides no revenue, pricing, or regulatory clearance details for the US.
This is a routine Form 4 insider purchase with no 10b5-1 plan disclosed; it may modestly support sentiment but is not a fundamental catalyst.
This is a routine insider-style accumulation signal, but it does not change fundamentals or provide new company guidance.
A disclosed insider/10% owner open-market purchase can modestly support near-term sentiment, but it is not a fundamental catalyst by itself.
alphai scores every news story that mentions CV with an AI model for sentiment and relevance, and aggregates insider trades from CapsoVision, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
CapsoVision, Inc (CV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CapsoVision Reports Second Quarter 2026 Financial Results SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financia
3 min readCapsoVision (NASDAQ: CV) said it launched its AI Highlights feature for the CapsoCam Plus capsule endoscopy system in international markets, including the EU. The AI flags suspected clinically relevant frames during standard processing and integrates with CapsoView and CapsoCloud workflows. The update is offered where authorized; it is not cleared by the FDA for US sale.
3 min readHARARI ELIYAHOU ET AL purchased 61,068 indirectly-held shares of CapsoVision, Inc (CV) at $6.73 ($0.41M total) on 2026-07-17.
2 min readHARARI ELIYAHOU ET AL purchased 81,300 indirectly-held shares of CapsoVision, Inc (CV) at $6.09 ($0.50M total) on 2026-07-08.
1 min readHARARI ELIYAHOU ET AL purchased 13,850 indirectly-held shares of CapsoVision, Inc (CV) at $7.35 ($0.10M total) on 2026-06-26.
1 min readCapsoVision (Nasdaq: CV) said it appointed gastroenterology leader David S. Shields, M.D., to its board effective July 1, 2026. Shields has served as a clinical advisor for nearly a decade. He replaces Joanne C. Imperial, who stepped down but will continue as an independent clinical consultant. The company cited upcoming milestones for AI-assisted reading and pipeline studies.
3 min readCapsoVision, Inc (CV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 cv-20260702xex1001.htm EX-10.1 Document Exhibit 10.01 Certain confidential information contained in this document, marked by [* * *], has been omitted pursuant to Item 601 (b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information
3 min readCapsoVision, Inc (CV) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cv-20260611 FALSE 0001378325 0001378325 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 8-K _________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
2 min readCapsoVision Inc (CV) is projected to report an earnings loss of 13 cents per share. This financial forecast comes from Refinitiv as an earnings preview. The article indicates it is a brief report, less than a minute read.
This article highlights three growth companies with significant insider ownership in the United States, suggesting that high insider ownership often signals strong commitment from those who understand the business best. The companies featured are CapsoVision (medical technology), Li Auto (electric vehicles), and Tutor Perini (construction), each with forecasts for strong earnings growth despite individual challenges or market conditions. The report encourages investors to consider these firms as part of a broader strategy focused on growth and insider confidence.
3 min read
